Orexo wins patent litigation for ZUBSOLV® in the US

Nikolaj Sørensen, President and CEO of Orexo AB, said: "I am very pleased that me and my team in both the US and Sweden, yet another time have received confirmation about the strength of our patents protecting the innovation and technology behind ZUBSOLV®. Since its launch in the US in 2013, ZUBSOLV® has generated more than SEK 4.7 billion in net revenues and will continue to be an important cash generator. I want to thank all our shareholders and, most importantly, the employees for their continued support and commitment during the last three years. Now we look forward to focusing on continuing to grow our business and bringing innovative treatment solutions to patients."

Nikolaj Sørensen, President and CEO of Orexo AB, said: "I am very pleased that me and my team in both the US and Sweden, yet another time have received confirmation about the strength of our patents protecting the innovation and technology behind ZUBSOLV®. Since its launch in the US in 2013, ZUBSOLV® has generated more than SEK 4.7 billion in net revenues and will continue to be an important cash generator. I want to thank all our shareholders and, most importantly, the employees for their continued support and commitment during the last three years. Now we look forward to focusing on continuing to grow our business and bringing innovative treatment solutions to patients."

For further information please contact:

Orexo AB (publ.)

About Orexo

Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health. The products are commercialized by Orexo in the US or via partners worldwide. The American market for buprenorphine/ naloxone products is the largest, where Orexo commercializes its lead product ZUBSOLV® for treatment of opioid use disorder. Total net sales for 2022 amounted to SEK 624 million and the number of employees was 126. Orexo is listed on the Nasdaq Stockholm Main Market (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.

For more information about Orexo please visit www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn, and YouTube.

The information in the press release is information that Orexo is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact person set out above, on July 1, 2023, at 11.20 am CET.

^[1] Q2 2022 – Q1 2023

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/orexo-wins-patent-litigation-for-zubsolv-in-the-us-301868534.html